A Study on the Cross-Mechanisms Between Metabolic Disorders and Alzheimer's Disease (AD)
Abstract
pathological diseases such as ?-amyloid deposition and abnormal Tau protein phosphorylation. It has been shown that metabolic abnormalities such as glucose metabolism, lipid metabolism deficiencies, insulin resistance, mitochondrial dysfunction, increased oxidative stress,
neuroinflammatory activation, gut microbiota imbalance, and vascular metabolic damage play an important role in AD development. It affects
brain energy, promotes A? deposition, increases abnormal Tau modification, disrupts blood-brain barrier homeostasis, and causes chronic
inflammatory response, forming a multipathological network leading to neuronal damage and cognitive decline. The study reviews the cross-mechanisms between metabolic disorders and AD, the relationships, key pathological pathways, and clinical implications, and discuss the
recent research regarding metabolic related biomarkers and comprehensive intervention. Removing the pathogenesis of AD from a metabolic
perspective may provide new theoretical basis for early screening, risk assessment, and complete intervention.
Keywords
Full Text:
PDFReferences
[1] Soto-Rojas LO, Pacheco-Herrero M, Martnez-Gmez PA, et al. The Neurovascular Unit Dysfunction in Alzheimer's Disease[J]. International Journal of Molecular Sciences, 2021, 22(4): 2022. DOI: 10.3390/ijms22042022.
[2] Pasqualetti G, Thayanandan T, Edison P. Influence of genetic and cardiometabolic risk factors in Alzheimer's disease[J]. Ageing Research Reviews, 2022, 81: 101723. DOI: 10.1016/j.arr.2022.101723.
[3] Choi H, Mook-Jung I. Functional effects of gut microbiota-derived metabolites in Alzheimer's disease[J]. Current Opinion in Neurobiology, 2023, 81: 102730. DOI: 10.1016/j.conb.2023.102730.
[4] Yin JT, Du YJ, Wang YQ, et al. The Influence of the Gut Microbiota on Alzheimer's Disease: A Narrative Review[J]. Journal of Integrative Neuroscience, 2023, 22(2): 38. DOI: 10.31083/j.jin2202038.
[5] Patel V, Edison P. Cardiometabolic risk factors and neurodegeneration: a review of the mechanisms underlying diabetes, obesity and hypertension in Alzheimer's disease[J]. Journal of Neurology, Neurosurgery & Psychiatry, 2024, 95(6): 581589. DOI: 10.1136/jnnp-2023-
332661.
[6] Luo YX, Yang LL, Yao XQ. Gut microbiota-host lipid crosstalk in Alzheimer's disease: implications for disease progression and
therapeutics[J]. Molecular Neurodegeneration, 2024, 19(1): 35. DOI: 10.1186/s13024-024-00720-0.
DOI: http://dx.doi.org/10.70711/pmr.v3i8.9541
Refbacks
- There are currently no refbacks.
